Vanguard Portfolio Management’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Portfolio Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-477,321	Closed	-$16M	–	3237
2026 Q1	$16M	Buy	+477,321	New	+$18.7M	﹤0.01%	1977

Vanguard Portfolio Management's SLNO Position: Q2 2026 in Review

Vanguard Portfolio Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 477,321 shares — an estimated $16M sold.

Vanguard Portfolio Management first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $16M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vanguard Portfolio Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Portfolio Management sold 477,321 Soleno Therapeutics shares in Q2 2026, an estimated $16M.
Vanguard Portfolio Management first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Portfolio Management's Soleno Therapeutics position peaked at $16M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.